^
    1m
    An Open-Label, Single-Arm Exploratory Clinical Study Evaluating the Efficacy and Safety of Intraperitoneal Perfusion of Recombinant Human Adenovirus Type 5 (H101) Combined with Tislelizumab, Platinum-Based, and Fluorouracil-Based Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Metastasis (ChiCTR2500107607)
    P=N/A, N=20, Not yet recruiting, Renji Hospital ,Shanghai Jiaotong University School Of Medicine; Renji Hospital ,Shanghai Jiaotong University School Of Medicine
    New trial
    |
    5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Oncorine (recombinant human adenovirus type 5)
    3ms
    Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University
    New P2 trial
    |
    Gendicine (rAd-p53 Gene Therapy)
    3ms
    ABCC1 promotes GSH-dependent iron transport and resistance to Fe(II) and Cu(II) chelators. (PubMed, Biometals)
    Cells expressing ABCC1 displayed significant resistance to thiosemicarbazones (Dp44mT, COTI-2, DpC) in both their metal-free and metal-bound forms. Vesicular transport assays further demonstrated that ABCC1 actively transports the Fe-GSH complex, formed under physiological glutathione levels, indicating its role in regulating the labile iron pool and reducing intracellular iron toxicity. These findings underscore the importance of transporter-chelator interactions in shaping drug resistance and sensitivity and highlight the intricate roles of ABC transporters in modulating chelator activity.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • ABCC1 (ATP Binding Cassette Subfamily C Member 1)
    |
    COTI-2
    4ms
    PTCA199-8: Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Fudan University | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial primary completion date
    |
    AiRuiKa (camrelizumab) • Oncorine (recombinant human adenovirus type 5)
    4ms
    Phase II, open label, single center clinical study of oncolytic adenovirus H101 combined with PD-1 inhibitor for metastatic castration resistant prostate cancer that has failed standard treatment (ChiCTR2500105156)
    P2, N=25, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New P2 trial
    |
    Oncorine (recombinant human adenovirus type 5)
    4ms
    P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2025 --> May 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    TP53 mutation
    |
    Keytruda (pembrolizumab) • p53MVA
    5ms
    Oncolytic virus-mediated p53 activation boosts the antitumor immunity of a p53-transduced dendritic cell vaccine. (PubMed, NPJ Vaccines)
    Combination therapy significantly suppressed the growth of p53-mutant MC38 tumors by activating the antitumor immune response. Our results suggest that OBP-702-mediated presentation of p53 epitopes on tumor cells enhances the antitumor efficacy of Ad-p53 DCs against murine CC tumors by attracting p53-targeting CTLs.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IL4 (Interleukin 4) • ITGAX (Integrin Subunit Alpha X)
    |
    TP53 mutation • TP53 wild-type
    |
    pfifteloxin (OBP-702)
    5ms
    Induction of abscopal effect combining H101 oncolytic virotherapy with tislelizumab in a patient with advanced hepatocellular carcinoma: a case report. (PubMed, Am J Cancer Res)
    Rapid tumor shrinkage was associated with severe local inflammation and a reduction in peripheral white blood cell counts. These findings suggest that oncolytic virotherapy may elicit an abscopal effect by activating and recruiting immune cells into the tumor microenvironment.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    Tevimbra (tislelizumab-jsgr) • Oncorine (recombinant human adenovirus type 5)
    5ms
    Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML. (PubMed, J Hematol Oncol)
    Although the overall efficacy was modest, this study lays the groundwork for future studies with improved patient selection and combination approaches.
    P1 data • Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • CDK7 (Cyclin Dependent Kinase 7)
    |
    RUNX1 mutation
    |
    Venclexta (venetoclax) • azacitidine • BTX-A51
    5ms
    Overcoming immune resistance in advanced esophageal squamous cell carcinoma with recombinant human adenovirus type 5 by impacting the immune microenvironment: a case report. (PubMed, Front Immunol)
    We also observed significant increases in the expression of CD3, CD4, CD8, CD20 and IL-1β after two relapsed H101 treatments based on multiplex immunofluorescence analysis. Intralymphatic injection of H101 combined with chemotherapy and immunotherapy may represent a promising clinical strategy for advanced ESCC patients with recurrent lymph node metastasis.
    Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL1B (Interleukin 1, beta)
    |
    Oncorine (recombinant human adenovirus type 5)
    5ms
    Disulfide-based 2-pyridyl-hydrazone prochelators induce iron deprivation and oxidative stress in ovarian cancer cells. (PubMed, J Biol Inorg Chem)
    We report the synthesis and biological evaluation of disulfide-based prochelators featuring a 2-pyridyl-hydrazone motif and resulting in a tridentate (S,N,N) donor set as found in several antiproliferative chelators (e.g., Triapine, Dp44mT, DpC, COTI-2). Accordingly, the preformed iron complex FePH3 also leads to apoptosis and iron dysregulation, and its toxicity is enhanced when the antioxidant capacity of the cells is impaired. The incorporation of the 2-pyridyl-hydrazone motif in disulfide-based prochelators therefore combines iron sequestration with pro-oxidant effects that could enhance the pharmacological profile of this chelation approach for cancer applications.
    Journal
    |
    TFRC
    |
    COTI-2 • Triapine (3-AP)
    6ms
    A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors (clinicaltrials.gov)
    P1, N=18, Suspended, SynerGene Therapeutics, Inc. | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • topotecan • SGT-53